Moo-Kang Kim

Moo-Kang Kim

Auto-generated profile, based on publicly available information

Moo-Kang Kim

Department of Internal Medicine (M.-K.K., H.-J.C., H.-S.K.), Seoul National University Hospital, South Korea

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2019 in Science
Verified
Journal Article
Closed access
PDF file
RHRonan Hinchet
Ronan Hinchet
HYHong-Joon Yoon
Hong-Joon Yoon
HRHanjun Ryu
Hanjun Ryu
MKMoo-Kang Kim
Moo-Kang Kim
ECEue-Keun Choi
Eue-Keun Choi
SKSang-Woo Kim
Sang-Woo Kim
A sound way to deliver power: Implanted medical devices, such as pacemakers and neurological stimulators, require a source of power, usually in the form of a battery. If a battery is implanted with the device, replacing it would require additional surgery. On the other hand, external power packs are prone to lead to infections where their wires enter the body. Hinchet et al. describe a triboelectric generator that can convert externally applied ultrasound into an internal electricity source capable of delivering sufficient energy to recharge a battery on a daily basis. Science , this issue p. 491

8 November 2024 in Circulation Research
Verified
Journal Article
Closed access
MKMinjun Kang
Minjun Kang
CLChoon-Soo Lee
Choon-Soo Lee
HSHyunJu Son
HyunJu Son
JLJeongha Lee
Jeongha Lee
JLJaewon Lee
Jaewon Lee
HKHyoSoo Kim
HyoSoo Kim
BACKGROUND: Latrophilin-2 (Lphn2), an adhesive GPCR (G protein-coupled receptor), was found to be a specific marker of cardiac progenitors during the differentiation of pluripotent stem cells into cardiomyocytes or during embryonic heart development in our previous studies. Its role in adult heart physiology, however, remains unclear. METHODS: The embryonic lethality resulting from Lphn2 deletion necessitates the establishment of cardiomyocyte-specific, tamoxifen-inducible Lphn2 knockout mice, which was achieved by crossing Lphn2  flox/flox mice with mice having MerCreMer (tamoxifen-inducible Cre [Cyclization recombinase] recombinase) under the α-myosin heavy chain promoter. RESULTS: Tamoxifen treatment for several days completely suppressed Lphn2 expression, specifically in the myocardium, and induced the dilated cardiomyopathy (D-CMP) phenotype with serious arrhythmia and sudden death in a short period of time. Transmission electron microscopy showed mitochondrial abnormalities, blurred Z-discs, and dehiscent myofibrils. The D-CMP phenotype, or heart failure, worsened during myocardial infarction. In a mechanistic study of D-CMP, Lphn2 knockout suppressed PGC-1α (Peroxisome proliferator-activated receptor gamma coactivator 1-alpha) and mitochondrial dysfunction, leading to the accumulation of reactive oxygen species and the global suppression of junctional molecules, such as N-cadherin (adherens junction), DSC-2 (desmocollin-2; desmosome), and connexin-43 (gap junction), leading to the dehiscence of cardiac myofibers and serious arrhythmia. In an experimental therapeutic trial, activators of p38-MAPK (p38 mitogen-activated protein kinases), which is a downstream signaling molecule of Lphn2, remarkably rescued the D-CMP phenotype of Lphn2 knockout in the heart by restoring PGC-1α and mitochondrial function and recovering global junctional proteins. CONCLUSIONS: Lphn2 is a critical regulator of heart integrity by controlling mitochondrial functions and cell-to-cell junctions in cardiomyocytes. Its deficiency leads to D-CMP, which can be rescued by activators of the p38-MAPK pathway.